So, for AD diagnosis, a combination of several tools is used, which include the clinical examination by magnetic resonance imaging (MRI) for the mesial temporal lobe atrophy or, more recently, functional-connectivity MRI; positron emission tomography (PET) to detect Aβ deposits, Tau presence or abnormal brain metabolism by 18F-fluorodeoxyglucose (FDG); Cerebrospinal fluid (CSF) assays to detect Aβ42, total Tau, threonine 181 (T181) phosphor-Tau and neurofilament light chain; and neuropsychological tests to assess cognitive performance [10,18]. Here, MAPT is linked to Alzheimer disease.